)
Edge23 Jan 2026
Death, Taxes, and Garbage: The Story of WM
How Waste Management turned garbage into one of America's most stable business models through landfills, regulation, and nationwide scale.
Incyte
Incyte (INCY) investor relations material
Incyte 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary12 Jan, 2026
Strategic vision and business model
Transitioning from a single-product focus to a diversified Hem-Onc-IAI company, aiming for top-tier revenue growth and durable cash flow through focused innovation and operational discipline.
Targeting $3-4 billion core business revenue (excluding Jakafi) by 2030, with plans to triple current levels and maintain a 15%-20% CAGR over five years.
R&D investment in 2026 will exceed $2 billion, with 80% allocated to seven priority compounds, eliminating diffuse spending.
Business development and capital allocation strategies target high-fit opportunities to create durable revenue and cash flow, leveraging a strong balance sheet.
Strategic focus on building franchises for operational and financial advantages, providing clarity for employees and predictability for investors.
Financial performance and growth outlook
2024 sales reached $3.62 billion, with 2025 guidance of $4.23-$4.32 billion, driven by strong Jakafi performance and 45% YoY core business growth.
Core business (excluding Jakafi) projected to reach $3-4 billion by 2030, supported by new product launches and a robust pipeline.
Opzelura, Niktimvo, and Monjuvi are the largest growth contributors, with Opzelura sales expected to double by 2030.
By 2030, the core business (ex-Jakafi) could match current Jakafi size, with minimal LOE exposure and a balance sheet of $7-$8 billion.
Jakafi XR launch in mid-2026 and continued growth in PV, MF, and GVHD segments.
Pipeline and product development
Seven high-value pipeline assets form three franchises, with six in phase III and most being novel or first-in-class agents.
Pipeline peak sales opportunity estimated north of $10 billion, with 14 pivotal trials across these assets by year-end.
Major pipeline assets include 989 (CALR inhibitor), 058 (JAK2V617F), 890 (TGFBR2xPD-1), and 734 (KRASG12D), all with pivotal trials and data readouts scheduled through 2026.
Povorcitinib positioned for $1B+ opportunity across hidradenitis suppurativa, vitiligo, and prurigo nodularis, with regulatory filings and data readouts in 2026.
Multiple assets advancing from early- to late-stage development, with regulatory submissions for Jakafi XR, Opzelura, and povorcitinib in 2025.
What drives confidence in $10B+ pipeline sales?
Identify top 3 drivers for ex-Jakafi $3-4B by 2030.
What is '989's disease-modifying potential?
What is the timeline for 989 pivotal trials?
What drives Opzelura's projected 2x growth?
How will OpEx be managed during the LOE trough?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Incyte earnings date
Q4 202510 Feb, 2026
Incyte
Next Incyte earnings date
Q4 202510 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Incyte is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company develops next generation medicines across its three core therapeutic platforms: cancer immunology, epigenetics and targeting microRNAs. The company's epigenetics platform is focused on technologies that can reprogram adult cells to their embryonic state to make them fertile ground for drug discovery.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage